OKYO Pharma Announces Chairman Acquires Shares
10 sept. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
05 sept. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
27 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma CEO Interview to Air on Bloomberg TV
23 août 2024 09h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
23 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
21 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
15 août 2024 12h13 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
06 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
10 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...